JHOP - October 2021 Vol 11, No 5

Original Article

Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?

Joseph Bubalo, PharmD, BCPS, BCOP

Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine

Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD

Original Article

Outcomes of Pharmacist-Provided Telehealth Services in an Ambulatory Oncology Clinic During the COVID-19 Pandemic

Colleen Bohnenkamp, PharmD, BCOP, BCPS; Grace A. Martin, PharmD, BCOP; Laure Dubois, PharmD, BCOP; Olivia Fahey, PharmD, BCOP; Jade Hefler, PharmD

Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment

Jessica McKernan, PharmD, BCOP; Laura Schmidt, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP

Efficacy of an Enteral Urine Alkalinization Strategy During Intravenous Sodium Bicarbonate Shortage in Patients with Cancer Receiving High-Dose Methotrexate

Christopher Sinoimeri, PharmD; Matthew Lei, PharmD, BCOP; Stephanie Monaco, PharmD, BCOP; Uvette Lou, PharmD, BCOP

Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma

Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease

Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors

Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.